Back to Search
Start Over
Opportunities and challenges: interleukin-22 comprehensively regulates polycystic ovary syndrome from metabolic and immune aspects
- Source :
- Journal of Ovarian Research, Vol 16, Iss 1, Pp 1-12 (2023)
- Publication Year :
- 2023
- Publisher :
- BMC, 2023.
-
Abstract
- Abstract Polycystic ovary syndrome (PCOS) is known as a prevalent but complicated gynecologic disease throughout the reproductive period. Typically, it is characterized by phenotypic manifestations of hyperandrogenism, polycystic ovary morphology, and persistent anovulation. For now, the therapeutic modality of PCOS is still a formidable challenge. Metabolic aberrations and immune challenge of chronic low-grade inflammatory state are significant in PCOS individuals. Recently, interleukin-22 (IL-22) has been shown to be therapeutically effective in immunological dysfunction and metabolic diseases, which suggests a role in the treatment of PCOS. In this review, we outline the potential mechanisms and limitations of IL-22 therapy in PCOS-related metabolic disorders including its regulation of insulin resistance, gut barrier, systemic inflammation, and hepatic steatosis to generate insights into developing novel strategies in clinical practice.
- Subjects :
- PCOS
IL-22
Metabolism
Treatment
Mechanism
Gynecology and obstetrics
RG1-991
Subjects
Details
- Language :
- English
- ISSN :
- 17572215
- Volume :
- 16
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Journal of Ovarian Research
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.6311ed02004428cb9f2ff78b2312b1b
- Document Type :
- article
- Full Text :
- https://doi.org/10.1186/s13048-023-01236-9